These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 24279293)

  • 1. EGFR inhibitors erlotinib and lapatinib ameliorate epidermal blistering in pemphigus vulgaris in a non-linear, V-shaped relationship.
    Sayar BS; Rüegg S; Schmidt E; Sibilia M; Siffert M; Suter MM; Galichet A; Müller EJ
    Exp Dermatol; 2014 Jan; 23(1):33-8. PubMed ID: 24279293
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Apoptotic mechanism in pemphigus autoimmunoglobulins-induced acantholysis--possible involvement of the EGF receptor.
    Frusić-Zlotkin M; Raichenberg D; Wang X; David M; Michel B; Milner Y
    Autoimmunity; 2006 Nov; 39(7):563-75. PubMed ID: 17101500
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intraperitoneal injection of pemphigus vulgaris-IgG into mouse depletes epidermal keratinocytes of desmoglein 3 associated with generation of acantholysis.
    Shu E; Yamamoto Y; Aoyama Y; Kitajima Y
    Arch Dermatol Res; 2007 Jun; 299(3):165-7. PubMed ID: 17431647
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Signalling pathways in pemphigus vulgaris.
    Li X; Ishii N; Ohata C; Furumura M; Hashimoto T
    Exp Dermatol; 2014 Mar; 23(3):155-6. PubMed ID: 24387643
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The role of nitric oxide synthases in pemphigus vulgaris in a mouse model.
    Marquina M; España A; Fernández-Galar M; López-Zabalza MJ
    Br J Dermatol; 2008 Jul; 159(1):68-76. PubMed ID: 18476963
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Desmoglein 1 and 3 enzyme-linked immunosorbent assay in Iranian patients with pemphigus vulgaris: correlation with phenotype, severity, and disease activity.
    Daneshpazhooh M; Chams-Davatchi C; Khamesipour A; Mansoori P; Taheri A; Firooz A; Mortazavi H; Esmaili N; Dowlati Y
    J Eur Acad Dermatol Venereol; 2007 Nov; 21(10):1319-24. PubMed ID: 17958835
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibition of FAK prevents blister formation in the neonatal mouse model of pemphigus vulgaris.
    Gil MP; Modol T; España A; López-Zabalza MJ
    Exp Dermatol; 2012 Apr; 21(4):254-9. PubMed ID: 22320676
    [TBL] [Abstract][Full Text] [Related]  

  • 8. IgG autoantibodies directed against desmoglein 3 cause dissociation of keratinocytes in canine pemphigus vulgaris and paraneoplastic pemphigus.
    Nishifuji K; Olivry T; Ishii K; Iwasaki T; Amagai M
    Vet Immunol Immunopathol; 2007 Jun; 117(3-4):209-21. PubMed ID: 17350107
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pemphigus mouse model as a tool to evaluate various immunosuppressive therapies.
    Takae Y; Nishikawa T; Amagai M
    Exp Dermatol; 2009 Mar; 18(3):252-60. PubMed ID: 18643850
    [TBL] [Abstract][Full Text] [Related]  

  • 10. MAPKAP kinase 2 (MK2)-dependent and -independent models of blister formation in pemphigus vulgaris.
    Mao X; Li H; Sano Y; Gaestel M; Mo Park J; Payne AS
    J Invest Dermatol; 2014 Jan; 134(1):68-76. PubMed ID: 23657501
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Are desmoglein autoantibodies essential for the immunopathogenesis of pemphigus vulgaris, or just "witnesses of disease"?
    Amagai M; Ahmed AR; Kitajima Y; Bystryn JC; Milner Y; Gniadecki R; Hertl M; Pincelli C; Kurzen H; Fridkis-Hareli M; Aoyama Y; Frusić-Zlotkin M; Müller E; David M; Mimouni D; Vind-Kezunovic D; Michel B; Mahoney M; Grando S
    Exp Dermatol; 2006 Oct; 15(10):815-31. PubMed ID: 16984264
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Explanations for the clinical and microscopic localization of lesions in pemphigus foliaceus and vulgaris.
    Mahoney MG; Wang Z; Rothenberger K; Koch PJ; Amagai M; Stanley JR
    J Clin Invest; 1999 Feb; 103(4):461-8. PubMed ID: 10021453
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Plakoglobin-dependent disruption of the desmosomal plaque in pemphigus vulgaris.
    de Bruin A; Caldelari R; Williamson L; Suter MM; Hunziker T; Wyder M; Müller EJ
    Exp Dermatol; 2007 Jun; 16(6):468-75. PubMed ID: 17518986
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of common epidermal growth factor receptor and HER2 variants on receptor activity and inhibition by lapatinib.
    Gilmer TM; Cable L; Alligood K; Rusnak D; Spehar G; Gallagher KT; Woldu E; Carter HL; Truesdale AT; Shewchuk L; Wood ER
    Cancer Res; 2008 Jan; 68(2):571-9. PubMed ID: 18199554
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pemphigus vulgaris IgG cause loss of desmoglein-mediated adhesion and keratinocyte dissociation independent of epidermal growth factor receptor.
    Heupel WM; Engerer P; Schmidt E; Waschke J
    Am J Pathol; 2009 Feb; 174(2):475-85. PubMed ID: 19147829
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibition of Rho A activity causes pemphigus skin blistering.
    Waschke J; Spindler V; Bruggeman P; Zillikens D; Schmidt G; Drenckhahn D
    J Cell Biol; 2006 Dec; 175(5):721-7. PubMed ID: 17130286
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An imbalance in Akt/mTOR is involved in the apoptotic and acantholytic processes in a mouse model of pemphigus vulgaris.
    Pretel M; España A; Marquina M; Pelacho B; López-Picazo JM; López-Zabalza MJ
    Exp Dermatol; 2009 Sep; 18(9):771-80. PubMed ID: 19552768
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dual-agent molecular targeting of the epidermal growth factor receptor (EGFR): combining anti-EGFR antibody with tyrosine kinase inhibitor.
    Huang S; Armstrong EA; Benavente S; Chinnaiyan P; Harari PM
    Cancer Res; 2004 Aug; 64(15):5355-62. PubMed ID: 15289342
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Novel targeted approaches to treating biliary tract cancer: the dual epidermal growth factor receptor and ErbB-2 tyrosine kinase inhibitor NVP-AEE788 is more efficient than the epidermal growth factor receptor inhibitors gefitinib and erlotinib.
    Wiedmann M; Feisthammel J; Blüthner T; Tannapfel A; Kamenz T; Kluge A; Mössner J; Caca K
    Anticancer Drugs; 2006 Aug; 17(7):783-95. PubMed ID: 16926628
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Protective effect of intravenous immunoglobulin (IVIG) in an experimental model of pemphigus vulgaris.
    Mimouni D; Blank M; Ashkenazi L; Milner Y; Frusic-Zlotkin M; Anhalt GJ; David M; Shoenfeld Y
    Clin Exp Immunol; 2005 Dec; 142(3):426-32. PubMed ID: 16297153
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.